US10092591B2ActiveUtilityA1
Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
Est. expiryFeb 27, 2034(~7.6 yrs left)· nominal 20-yr term from priority
A61K 31/661A61K 45/06A61K 31/166A61K 31/4439A61K 31/7076C07D 473/06A61K 38/57A61K 31/366A61K 31/522A61K 31/00
50
PatentIndex Score
0
Cited by
125
References
8
Claims
Abstract
Disclosed are compositions and methods for inducing therapeutic hypothermia in a subject.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A method of treating ischemic brain injury caused by cardiac arrest in a subject comprising administering to the subject a therapeutically effective amount of an A 1 adenosine receptor (A 1 AR) agonist and an A 1 AR antagonist, wherein the A 1 AR agonist is capadenoson, or a combination of capadenoson with N 6 -cyclohexyladenosine (CHA), and the A 1 AR antagonist is 8-p-sulfophenyltheophylline (8-SPT), wherein the A 1 AR agonist crosses the blood brain barrier and wherein the A 1 AR antagonist does not cross the blood-brain barrier, and wherein treating ischemic brain injury involves alleviating shivering in the subject.
2. The method of claim 1 , further comprising inducing therapeutic hypothermia in the subject.
3. The method of claim 2 , further comprising maintaining hypothermia in the subject.
4. The method of claim 3 , wherein maintaining hypothermia in the patient comprises repeating the administration of the A 1 AR agonist and the A 1 AR antagonist.
5. The method of claim 1 , wherein the A 1 AR agonist and the A 1 AR antagonist are co-administered.
6. The method of claim 1 , wherein the A 1 AR antagonist is titrated to minimize side effects of the agonist.
7. A method of controlling core body temperature in a subject comprising administering to the subject a therapeutically effective amount of an A 1 AR agonist and an A 1 AR antagonist, wherein the A 1 AR agonist is capadenoson or a combination of capadenoson with CHA, and the A 1 AR antagonist is 8-SPT, wherein the A 1 AR agonist crosses the blood brain barrier and wherein the A 1 AR antagonist does not cross the blood-brain barrier, wherein the A1AR agonist alleviates shivering.
8. The method of claim 7 , wherein the subject had an ischemic brain injury.Join the waitlist — get patent alerts
Track US10092591B2 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.